Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 362-363, 2007; 10.1373/clinchem.2006.080317
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, E. S.K.
Right arrow Articles by Lee, E. T.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, E. S.K.
Right arrow Articles by Lee, E. T.K.
Related Collections
Right arrow Clinical Immunology
Right arrow Hematology
(Clinical Chemistry. 2007;53:362-363.)
© 2007 American Association for Clinical Chemistry, Inc.

Letters to the Editor

A Case of IgM Paraproteinemia in Which Serum Free Light Chain Values Were Within Reference Intervals

Edmond S.K. Maa and Ernest T.K. Lee

Department of Pathology, Hong Kong Sanatorium and Hospital

aAddress correspondence to this author at: 1/F Li Shu Fan Block, Hong Kong Sanatorium & Hospital, 2 Village Road, Hong Kong. Fax 852-2835-8799; e-mail eskma@hksh.com.

The first 20% of the full text of this article appears below.


To the Editor:

We read with interest the recent paper on the combination of serum protein electrophoresis (SPEP) and serum free light chain (FLC) assay as a potential alternative to SPEP and urine protein electrophoresis (UPEP) screening for paraproteinemia (1), as well as the accompanying editorial on sensitivity and specificity issues of the serum FLC assay (2). This assay, which first became commercially available in 2001, is used to diagnose and monitor light chain myeloma, primary amyloidosis, and related light chain diseases. Despite the usually quoted high clinical sensitivity of serum FLC assay in detecting light chain disease, results within reference intervals can occur with intact immunoglobulin paraproteinemia (3). We describe a patient with IgM paraproteinemia who showed FLC concentrations and {kappa}:{lambda} ratio within reference intervals.

A 79-year old Chinese woman presented with blurred vision due to hyperviscosity syndrome and bleeding . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.